Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters

被引:85
|
作者
Can, Adem [1 ,4 ]
Zanos, Panos [1 ]
Moaddel, Ruin [5 ]
Kang, Hye Jin [6 ]
Dossou, Katinia S. S. [5 ]
Wainer, Irving W. [5 ,7 ]
Cheer, Joseph F. [1 ,3 ]
Frost, Douglas O. [1 ,2 ]
Huang, Xi-Ping [6 ]
Gould, Todd D. [1 ,2 ,3 ]
机构
[1] Univ Maryland, Sch Med, Dept Psychiat, Room 936 MSTF,685 West Baltimore St, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA
[4] Notre Dame Maryland Univ, Dept Psychol, Baltimore, MD USA
[5] NIA, Biomed Res Ctr, NIH, Baltimore, MD 21224 USA
[6] Univ N Carolina, Sch Med, Natl Inst Mental Hlth, Dept Pharmacol,Psychoact Drug Screening Program, Chapel Hill, NC USA
[7] Mitchell Woods Pharmaceut, Shelton, CT USA
关键词
METHYL-D-ASPARTATE; RAT PREFRONTAL CORTEX; ANTIDEPRESSANT EFFICACY; NMDA ANTAGONIST; IN-VITRO; DEPRESSION; SEROTONIN; NEURONS; MK-801; INHIBITION;
D O I
10.1124/jpet.116.235838
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Following administration at subanesthetic doses, (R,S)-ketamine (ketamine) induces rapid and robust relief from symptoms of depression in treatment-refractory depressed patients. Previous studies suggest that ketamine's antidepressant properties involve enhancement of dopamine (DA) neurotransmission. Ketamine is rapidly metabolized to (2S,6S)- and (2R,6R)-hydroxynorketamine (HNK), which have antidepressant actions independent of N-methyl-D-aspartate glutamate receptor inhibition. These antidepressant actions of (2S, 6S; 2R, 6R)- HNK, or other metabolites, as well as ketamine's side effects, including abuse potential, may be related to direct effects on components of the dopaminergic (DAergic) system. Here, brain and blood distribution/clearance and pharmacodynamic analyses at DA receptors (D1-D5) and the DA, norepinephrine, and serotonin transporters were assessed for ketamine and its major metabolites (norketamine, dehydronorketamine, and HNKs). Additionally, we measured electrically evoked mesolimbic DA release and decay using fast-scan cyclic voltammetry following acute administration of subanesthetic doses of ketamine (2, 10, and 50 mg/kg, i.p.). Following ketamine injection, ketamine, norketamine, and multiple hydroxynorketamines were detected in the plasma and brain of mice. Dehydronorketamine was detectable in plasma, but concentrations were below detectable limits in the brain. Ketamine did not alter the magnitude or kinetics of evoked DA release in the nucleus accumbens in anesthetized mice. Neither ketamine's enantiomers nor its metabolites had affinity for DA receptors or the DA, noradrenaline, and serotonin transporters ( up to 10 mu M). These results suggest that neither the side effects nor antidepressant actions of ketamine or ketamine metabolites are associated with direct effects on mesolimbic DAergic neurotransmission. Previously observed in vivo changes in DAergic neurotransmission following ketamine administration are likely indirect.
引用
收藏
页码:159 / 170
页数:12
相关论文
共 50 条
  • [31] Ketamine reduces cholinergic modulated GABA release from rat striatal slices
    Grasshoff, C
    Gillessen, T
    Wagner, E
    Thiermann, H
    Szinicz, L
    TOXICOLOGY LETTERS, 2005, 156 (03) : 361 - 367
  • [32] THE EFFECTS OF MONOAMINE-OXIDASE-B INHIBITION ON DOPAMINE METABOLISM IN RATS WITH NIGRO-STRIATAL LESIONS
    SCARR, E
    WINGERCHUK, DM
    JUORIO, AV
    PATERSON, IA
    NEUROCHEMICAL RESEARCH, 1994, 19 (02) : 153 - 159
  • [33] Effects of phentermine on striatal dopamine and serotonin release in conscious rats:: In vivo microdialysis study
    Balcioglu, A
    Wurtman, RJ
    INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 (04) : 325 - 328
  • [34] Effects of phentermine on striatal dopamine and serotonin release in conscious rats:In vivo microdialysis study
    A Balcioglu
    RJ Wurtman
    International Journal of Obesity, 1998, 22 : 325 - 328
  • [35] Lobelane Inhibits Methamphetamine-Evoked Dopamine Release via Inhibition of the Vesicular Monoamine Transporter-2
    Nickell, Justin R.
    Krishnamurthy, Sairam
    Norrholm, Seth
    Deaciuc, Gabriela
    Siripurapu, Kiran B.
    Zheng, Guangrong
    Crooks, Peter A.
    Dwoskin, Linda P.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 332 (02) : 612 - 621
  • [36] Striosome Circuitry Stimulation Inhibits Striatal Dopamine Release and Locomotion
    Okunomiya, Taro
    Watanabe, Dai
    Banno, Haruhiko
    Kondo, Takayuki
    Imamura, Keiko
    Takahashi, Ryosuke
    Inoue, Haruhisa
    JOURNAL OF NEUROSCIENCE, 2025, 45 (04)
  • [37] Striatal Dopamine Release Is Triggered by Synchronized Activity in Cholinergic Interneurons
    Threlfell, Sarah
    Lalic, Tatjana
    Platt, Nicola J.
    Jennings, Katie A.
    Deisseroth, Karl
    Cragg, Stephanie J.
    NEURON, 2012, 75 (01) : 58 - 64
  • [38] Whole-brain mapping reveals the divergent impact of ketamine on the dopamine system
    Datta, Malika S.
    Chen, Yannan
    Chauhan, Shradha
    Zhang, Jing
    De La Cruz, Estanislao Daniel
    Gong, Cheng
    Tomer, Raju
    CELL REPORTS, 2023, 42 (12):
  • [39] (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism
    Ago, Yukio
    Tanabe, Wataru
    Higuchi, Momoko
    Tsukada, Shinji
    Tanaka, Tatsunori
    Yamaguchi, Takumi
    Igarashi, Hisato
    Yokoyama, Rei
    Seiriki, Kaoru
    Kasai, Atsushi
    Nakazawa, Takanobu
    Nakagawa, Shinsaku
    Hashimoto, Kenji
    Hashimoto, Hitoshi
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2019, 22 (10) : 665 - 674
  • [40] Distinctive Modulation of Dopamine Release in the Nucleus Accumbens Shell Mediated by Dopamine and Acetylcholine Receptors
    Shin, Jung Hoon
    Adrover, Martin F.
    Alvarez, Veronica A.
    JOURNAL OF NEUROSCIENCE, 2017, 37 (46) : 11166 - 11180